University of Zürich

Marlen Knobloch

Jan Grimm

Roger Nitsch

Christoph Hock

Kathrin Tissot

Christoph Esslinger

Markus Rudin

Thomas Müggler

Felicitas Kranz

Uwe Konietzko

Christoph Prof Hock

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

Method of providing disease-specific binding molecules and targets

Methods of treating Alzheimer's disease

Provided is a novel APP (amyloid precursor protein) transgenic non-human animal modeling in vivo the pathophysiological effects and effects on cognitive behavior of early intraneuronal and extracellular brain parenchymal amyloid-&#x3b2; (A&#x3b2;) deposition and cerebral amyloid angiopathy associated with brain microhemorrhages and reduced vasoreactivity and blood flow. Furthermore, methods of screening for therapeutic or diagnostic agents useful in the treatment or diagnosis of Alzheimer's disease, in particular for improving blood flow to the brain are provided as well as the corresponding therapeutic methods.

Transgenic animal model for alzheimer's disease

Growing community of inventors

Tolochenaz, Switzerland

Marlen Knobloch